HUP0103465A2 - A VEGF expressziójának gátlására szolgáló rövid oligonukleotidok - Google Patents

A VEGF expressziójának gátlására szolgáló rövid oligonukleotidok

Info

Publication number
HUP0103465A2
HUP0103465A2 HU0103465A HUP0103465A HUP0103465A2 HU P0103465 A2 HUP0103465 A2 HU P0103465A2 HU 0103465 A HU0103465 A HU 0103465A HU P0103465 A HUP0103465 A HU P0103465A HU P0103465 A2 HUP0103465 A2 HU P0103465A2
Authority
HU
Hungary
Prior art keywords
seq
oligonucleotides
vegf
inhibition
expression
Prior art date
Application number
HU0103465A
Other languages
English (en)
Inventor
Alan Bitonti
Anuschirwan Peyman
Eugen Uhlmann
Richard Woessner
Original Assignee
Aventis Pharma Deutschland Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh. filed Critical Aventis Pharma Deutschland Gmbh.
Publication of HUP0103465A2 publication Critical patent/HUP0103465A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgyát rövid oligonukleotid vagy annak egy származékaképezi, amelynek szekvenciája VEGF-et (vaszkuláris endoteliálisnövekedési faktor) kódoló nukleinsav-szekvencia egy adott részleténekmegfelel és amely legfeljebb 15 nukleotid hosszúságú. A rövidoligonukleotidok szekvenciája például az alábbiak bármelyike: 1.azonosítószámú szekv.: 5'-CCCGGCCCCGGTCGGGCCTCCG-3', 2. azonosítószámúszekv.: 5'-CGGGCCTCCGAAACC-3', 3. azonosítószámú szekv.: 5'-GCTCTACCTCCACCATGCCAA-3', 4. azonosítószámú szekv.: 5'-GTGGTCCCAGGCTGCACCCATGGC-3', 5. azonosítószámú szekv.: 5'-CATCTTCAAGCCATCC-3', és 6. azonosítószámú szekv.: 5'-TGCGGGGGCTGCTGC-3'. A találmány tárgyát képezi továbbá az oligonukleotid alkalmazása aVEGF expressziójának gátlására, az oligonukleotidokat tartalmazógyógyászati készítmények, valamint eljárás az oligonukleotidokelőállítására és VEGF expressziójának gátlására. A találmány szerintioligonukleotidok és gyógyászati készítmények alkalmasak abnormálisvaszkuláris permeabilitással, sejtosztódással, sejtáthatolással,angiogenezissel, neovaszkularizációval, tumorsejt-növekedéssel és/vagymetasztázissal járó betegségek kezelésére. Ó
HU0103465A 1998-08-07 1999-07-29 A VEGF expressziójának gátlására szolgáló rövid oligonukleotidok HUP0103465A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98114853A EP0979869A1 (en) 1998-08-07 1998-08-07 Short oligonucleotides for the inhibition of VEGF expression
PCT/EP1999/005433 WO2000008141A2 (en) 1998-08-07 1999-07-29 Short oligonucleotides for the inhibition of vegf expression

Publications (1)

Publication Number Publication Date
HUP0103465A2 true HUP0103465A2 (hu) 2002-01-28

Family

ID=8232420

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103465A HUP0103465A2 (hu) 1998-08-07 1999-07-29 A VEGF expressziójának gátlására szolgáló rövid oligonukleotidok

Country Status (9)

Country Link
US (1) US20010021772A1 (hu)
EP (2) EP0979869A1 (hu)
JP (1) JP2002524038A (hu)
KR (1) KR20010085347A (hu)
AU (1) AU5415099A (hu)
CA (1) CA2339416A1 (hu)
HU (1) HUP0103465A2 (hu)
PL (1) PL346170A1 (hu)
WO (1) WO2000008141A2 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1252308A2 (en) * 2000-01-19 2002-10-30 Parkash S. Gill Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides
DK1446162T3 (da) 2001-08-17 2008-12-08 Coley Pharm Gmbh Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet
ATE314096T1 (de) 2001-10-03 2006-01-15 Bioniche Life Sciences Inc Therapeutisch verwendbare triethylenglykol- cholesteryl-oligonukleotide
US20050222061A1 (en) 2002-04-18 2005-10-06 Schulte Ralf W Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
MXPA06007269A (es) * 2003-12-23 2007-07-09 Univ Pennsylvania Composiciones y metodos para terapia combinada de enfermedad.
EP1812473A4 (en) 2004-11-16 2009-12-23 Univ Boston DUAL ENDOTHELIN-1 / ANGIOTENSIN II RECEPTOR (DEAR) FUNCTIONS IN HYPERTONIA AND ANGIOGENESIS
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
AU2007257094B2 (en) 2006-05-05 2012-10-25 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of SGLT2
US20090130212A1 (en) * 2006-05-15 2009-05-21 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
PT2029746E (pt) * 2006-06-12 2012-10-15 Exegenics Inc D B A Opko Health Inc Composições e métodos para a inibição do sirna de angiogenese
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
WO2010065834A1 (en) 2008-12-04 2010-06-10 Opko Ophthalmics, Llc Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
MX2011005912A (es) 2008-12-04 2011-06-17 Opko Curna Llc Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
US8975019B2 (en) * 2009-10-19 2015-03-10 University Of Massachusetts Deducing exon connectivity by RNA-templated DNA ligation/sequencing
WO2011109427A2 (en) 2010-03-01 2011-09-09 Alnylam Pharmaceuticals, Inc. Improving the biological activity of sirna through modulation of its thermodynamic profile
KR101350919B1 (ko) * 2011-03-14 2014-01-14 (주)바이오니아 핵산을 포함하는 물체의 식별 방법
JP6129844B2 (ja) 2011-09-14 2017-05-17 ラナ セラピューティクス インコーポレイテッド 多量体オリゴヌクレオチド化合物
WO2014043544A1 (en) 2012-09-14 2014-03-20 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
WO2020109344A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Occular administration device for antisense oligonucleotides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
EP0769552A4 (en) * 1994-06-27 1997-06-18 Toagosei Co Ltd ANTISENSE NUCLEIC ACID COMPOUND
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
JPH09286795A (ja) * 1996-04-18 1997-11-04 Toagosei Co Ltd 核酸化合物

Also Published As

Publication number Publication date
AU5415099A (en) 2000-02-28
PL346170A1 (en) 2002-01-28
CA2339416A1 (en) 2000-02-17
EP1100894A2 (en) 2001-05-23
EP0979869A1 (en) 2000-02-16
JP2002524038A (ja) 2002-08-06
WO2000008141A3 (en) 2000-05-18
US20010021772A1 (en) 2001-09-13
WO2000008141A2 (en) 2000-02-17
KR20010085347A (ko) 2001-09-07

Similar Documents

Publication Publication Date Title
HUP0103465A2 (hu) A VEGF expressziójának gátlására szolgáló rövid oligonukleotidok
US20180179526A1 (en) Method and Medicament For Inhibiting The Expression of A Given Gene
Schmeissner et al. Removal of a terminator structure by RNA processing regulates int gene expression
Wang et al. Genomic organization and chromosomal location of the human dsRNA adenosine deaminase gene: the enzyme for glutamate-activated ion channel RNA editing
CA2117903C (en) Targeted cleavage of rna using eukaryotic ribonuclease and external guide sequence
DK0664833T3 (da) Terapeutisk anti-HIV oligonukletid og lægemiddel
CA2088917A1 (en) Therapeutic ribozyme compositions
NO901213L (no) Genetiske enheter for inhibering av rna-funksjonen.
HUP9702377A2 (hu) Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek
DE69432315D1 (de) ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT
YU91901A (sh) Oligonukleotidi za inhibiciju ekspresije humanog gena koji kodira eg5
Bailly et al. The influence of the 2‐amino group of guanine on DNA conformation. Uranyl and DNase I probing of inosine/diaminopurine substituted DNA.
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
AU6123496A (en) Processes for the identification of compounds which control cell behaviour, the compounds identified and pharmaceutical compositions containing them and their use in the control of cell behaviour
Hovemann et al. Heat-shock locus 93D of Drosophila melanogaster: An RNA with limited coding capacity accumulates precursor transcripts after heat shock
AP1674A (en) The genome of the HIV-1 inter-subtype (C/B') and use thereof.
HUP0101355A2 (hu) Fehérjetermelésre és célba juttatására szolgáló genomi szekvenciák
HUP9801681A2 (hu) Mutáns proteinek
ES2112062T3 (es) Oligonucleotidos con actividad anti-citomegalovirus.
HUP0100044A1 (hu) A humán Ha-ras gén egy szakaszával komplementer, módosított antiszensz oligonukleotidok
WO1993014768A1 (en) Methods and compositions for neutralizing intracellular nucleic acid-binding protein biological activity in a cell, including methods and compositions useful to regulate gene function
ITMI20030860A1 (it) Metodo per l'inibizione selettiva del gene n-myc
Chen et al. Ubiquitylation and destruction of endogenous c-mycS by the proteasome: are myc boxes dispensable?
DE69730967D1 (en) Human dnase ii